Last reviewed · How we verify
TAK-935 Tablets
At a glance
| Generic name | TAK-935 Tablets |
|---|---|
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Soticlestat in Adults and Children With Rare Epilepsies (PHASE2)
- A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome (PHASE3)
- A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine (PHASE3)
- A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome (PHASE3)
- A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome (PHASE3)
- A Study of Soticlestat Tablets in Healthy Adults (PHASE1)
- A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function (PHASE1)
- A Study of Soticlestat and Rifampin in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAK-935 Tablets CI brief — competitive landscape report
- TAK-935 Tablets updates RSS · CI watch RSS
- Takeda portfolio CI